IMMUNOLOGICAL APPROACHES TO ASSESSING THE RESPONSE TO INACTIVATED HEPATITIS-A VACCINE

被引:24
|
作者
LEMON, SM
机构
[1] The University of North Carolina at Chapel Hill, Chapel Hill
关键词
HEPATITIS A VIRUS; VIRUS NEUTRALIZATION; IMMUNOASSAY; VACCINE; IMMUNITY;
D O I
10.1016/S0168-8278(05)80372-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Natural immunity to hepatitis A virus (HAV) is complex and likely to involve several distinct arms of the immune system. There is evidence that natural killer cells, human leukocyte antigen (HLA)-restricted cytotoxic T cells, and antibody-secreting cells of B-cell lineage all play roles in the immune response to infection with HAV. However, antibody alone is sufficient to provide a high level of protection against clinical disease. A comparison of the serum levels of antibody to HAV (anti-HAV) following administration of immune serum globulin and hepatitis A vaccine may provide a useful estimate of vaccine efficacy. Such comparisons may be accomplished using solid-phase immunoassays for detection of anti-HAV. However, tests which measure antibody capable of neutralizing virus in vitro are generally more sensitive than solid-phase immunoassays. The use of endogenously labelled virus in-radioimmunoprecipitation assays shows promise of providing an equally sensitive means of measuring antibodies which are reactive with HAV particles.
引用
收藏
页码:S15 / S19
页数:5
相关论文
共 50 条
  • [31] IMMUNOGENICITY OF INACTIVATED HEPATITIS-A VIRAL VACCINE OF CELL-CULTURE ORIGIN
    KUSOV, YY
    ELBERT, LB
    KAZACHKOV, YA
    VALYANO, NM
    NELGA, IV
    GRISHINA, GK
    KRUTYANSKAYA, GL
    LISITSYNA, EA
    POLESHCHUK, VF
    SOBOL, AV
    TITOVA, IP
    KARPOVICH, LG
    KALASHNIKOVA, TV
    BALAYAN, MS
    VOPROSY VIRUSOLOGII, 1991, 36 (03) : 206 - 209
  • [32] IMMUNOGENICITY AND SAFETY OF A NEW INACTIVATED HEPATITIS-A VACCINE IN A COMPARATIVE-STUDY
    GOILAV, C
    ZUCKERMAN, J
    LAFRENZ, M
    VIDOR, E
    LAUWERS, S
    RATHEAU, C
    BENICHOU, G
    ZUCKERMAN, A
    JOURNAL OF MEDICAL VIROLOGY, 1995, 46 (03) : 287 - 292
  • [33] INACTIVATED HEPATITIS-A VACCINE - A SAFETY AND IMMUNOGENICITY STUDY IN HEALTH-PROFESSIONALS
    DAVIDSON, M
    KRUGMAN, S
    SANDMAN, LA
    VACCINE, 1992, 10 : S119 - S120
  • [34] SAFETY AND IMMUNOGENICITY OF AN INACTIVATED HEPATITIS-A CANDIDATE VACCINE IN HEALTHY ADULT VOLUNTEERS
    WIEDERMANN, G
    AMBROSCH, F
    KOLLARITSCH, H
    HOFMANN, H
    KUNZ, C
    DHONDT, E
    DELEM, A
    ANDRE, FE
    SAFARY, A
    STEPHENNE, J
    VACCINE, 1990, 8 (06) : 581 - 584
  • [35] INACTIVATED HEPATITIS-A VACCINE - A SAFETY AND IMMUNOGENICITY STUDY IN HEALTH-PROFESSIONALS
    SANDMAN, L
    DAVIDSON, M
    KRUGMAN, S
    JOURNAL OF INFECTIOUS DISEASES, 1995, 171 : S50 - S52
  • [36] FIELD EFFICACY TRIAL OF INACTIVATED HEPATITIS-A VACCINE AMONG CHILDREN IN THAILAND
    INNIS, BL
    SNITBHAN, R
    KUNASOL, P
    LAORAKPONGSE, T
    POOPATANAKOOL, W
    SUNTAYAKORN, S
    SUKNANTAPONG, T
    SAFARY, A
    BOSLEGO, JW
    VACCINE, 1992, 10 : S159 - S159
  • [37] SAFETY AND DOSE RELATED IMMUNOGENICITY OF AN INACTIVATED HEPATITIS-A VIRUS-VACCINE
    SHOUVAL, D
    ELLERBECK, E
    LEWIS, J
    ASHUR, Y
    NALIN, D
    CALANDRA, G
    MIDTHUN, K
    HEPATOLOGY, 1990, 12 (02) : 439 - 439
  • [38] IMMUNOGENICITY TRIAL OF INACTIVATED HEPATITIS-A VIRUS-VACCINE IN HUMAN VOLUNTEERS
    KUSOV, YY
    ELBERT, LB
    NELGA, IV
    GRISHINA, GK
    DUNAEVSKI, OA
    KHARIN, NV
    MASLOV, YN
    DROZDOV, SG
    BALAYAN, MS
    VACCINE, 1991, 9 (08) : 540 - 541
  • [39] CLINICAL-TRIAL WITH INACTIVATED HEPATITIS-A VACCINE AND RECOMMENDATIONS FOR ITS USE
    TILZEY, AJ
    PALMER, SJ
    BARROW, S
    PERRY, KR
    TYRRELL, H
    SAFARY, A
    BANATVALA, JE
    BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6837): : 1272 - 1276
  • [40] SAFETY AND IMMUNOGENICITY OF AN INACTIVATED HEPATITIS-A VACCINE - EFFECT OF DOSE AND VACCINATION SCHEDULE
    WESTBLOM, TU
    GUDIPATI, S
    DEROUSSE, C
    MIDKIFF, BR
    BELSHE, RB
    JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (05): : 996 - 1001